Identification

Name
Remifentanil
Accession Number
DB00899  (APRD01216)
Type
Small Molecule
Groups
Approved
Description

Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist. Hence, it causes a reduction in sympathetic nervous system tone, respiratory depression and analgesia.

Structure
Thumb
Synonyms
  • REMIFENTANIL
  • Remifentanyl
External IDs
GI 87084X / IDS-NR-005
Product Ingredients
IngredientUNIICASInChI Key
Remifentanil hydrochloride5V444H5WIC132539-07-2WFBMIPUMYUHANP-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Remifentanil for InjectionPowder, for solution2 mgIntravenousTeva2014-06-05Not applicableCanada
Remifentanil for InjectionPowder, for solution2 mgIntravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Remifentanil for InjectionPowder, for solution1 mgIntravenousTeva2014-06-05Not applicableCanada
Remifentanil for InjectionPowder, for solution1 mgIntravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Remifentanil Hydrochloride for InjectionPowder, for solution1 mgIntravenousSterimax Inc2011-09-27Not applicableCanada
Remifentanil Hydrochloride for InjectionPowder, for solution5 mgIntravenousSterimax IncNot applicableNot applicableCanada
Remifentanil Hydrochloride for InjectionPowder, for solution2 mgIntravenousSterimax Inc2011-09-29Not applicableCanada
UltivaInjection, powder, lyophilized, for solution1 mg/mLIntravenousMylan Institutional1996-11-06Not applicableUs
UltivaPowder, for solution1 mgIntravenousAbbvie1997-04-072013-10-02Canada
UltivaPowder, for solution5 mgIntravenousAbbvie1997-03-172013-10-02Canada
Categories
UNII
P10582JYYK
CAS number
132875-61-7
Weight
Average: 376.4467
Monoisotopic: 376.199822016
Chemical Formula
C20H28N2O5
InChI Key
ZTVQQQVZCWLTDF-UHFFFAOYSA-N
InChI
InChI=1S/C20H28N2O5/c1-4-17(23)22(16-8-6-5-7-9-16)20(19(25)27-3)11-14-21(15-12-20)13-10-18(24)26-2/h5-9H,4,10-15H2,1-3H3
IUPAC Name
methyl 1-(3-methoxy-3-oxopropyl)-4-(N-phenylpropanamido)piperidine-4-carboxylate
SMILES
CCC(=O)N(C1=CC=CC=C1)C1(CCN(CCC(=O)OC)CC1)C(=O)OC

Pharmacology

Indication

For use during the induction and maintenance of general anesthesia.

Structured Indications
Not Available
Pharmacodynamics

Remifentanil is an opioid agonist with rapid onset and peak effect and ultra-short duration of action. The opioid activity of remifentanil is antagonized by opioid antagonists such as naloxone. The analgesic effects of remifentanil are rapid in onset and offset. Its effects and side effects are dose dependent and similar to other opioids. Remifentanil in humans has a rapid blood-brain equilibration half-time of 1 ± 1 minutes (mean ± SD) and a rapid onset of action.

Mechanism of action

Remifentanil is a µ-opioid agonist with rapid onset and peak effect, and short duration of action. The µ-opioid activity of remifentanil is antagonized by opioid antagonists such as naloxone.

TargetActionsOrganism
AMu-type opioid receptor
agonist
Human
UDelta-type opioid receptor
agonist
Human
UKappa-type opioid receptor
agonist
Human
Absorption
Not Available
Volume of distribution
  • 350 mL/kg
  • 452 ± 144 mL/kg [neonates]
  • 223 ± 30.6 mL/kg [adolescents]
Protein binding

70% (bound to plasma proteins)

Metabolism

By hydrolysis of the propanoic acid-methyl ester linkage by nonspecific blood and tissue esterases.

Route of elimination

Remifentanil is an esterase-metabolized opioid. The carboxylic acid metabolite is essentially inactive (1/4600 as potent as remifentanil in dogs) and is excreted by the kidneys with an elimination half-life of approximately 90 minutes.

Half life

1-20 minutes

Clearance
  • 40 mL/min/kg [young, healthy adults]
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Remifentanil Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Remifentanil.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Remifentanil.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Remifentanil.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Remifentanil is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineRemifentanil may increase the serotonergic activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Remifentanil is combined with Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Acetazolamide.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Remifentanil.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Remifentanil is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Agomelatine.Approved, Investigational
AlaproclateRemifentanil may increase the serotonergic activities of Alaproclate.Experimental
AlcuroniumThe risk or severity of adverse effects can be increased when Alcuronium is combined with Remifentanil.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Aldesleukin.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Remifentanil.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Remifentanil.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Remifentanil is combined with Aliskiren.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Remifentanil.Approved, Illicit, Investigational
AlprenololRemifentanil may increase the bradycardic activities of Alprenolol.Approved, Withdrawn
AlvimopanThe risk or severity of adverse effects can be increased when Remifentanil is combined with Alvimopan.Approved
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Remifentanil.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Amiloride.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Remifentanil.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Amitriptyline.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Amlodipine.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Remifentanil which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Remifentanil is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Remifentanil.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Remifentanil.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Remifentanil is combined with Amyl Nitrite.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Remifentanil.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Remifentanil.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Apraclonidine.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Remifentanil.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Remifentanil.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Remifentanil.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Asenapine.Approved
AtenololThe risk or severity of adverse effects can be increased when Remifentanil is combined with Atenolol.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Atracurium is combined with Remifentanil.Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Remifentanil.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Remifentanil.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Azaperone.Investigational, Vet Approved
AzelastineRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Azilsartan medoxomil.Approved
AzosemideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Remifentanil is combined with Baclofen.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Remifentanil.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Remifentanil is combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Remifentanil.Approved
BefunololRemifentanil may increase the bradycardic activities of Befunolol.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Remifentanil.Withdrawn
BenazeprilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Bendroflumethiazide.Approved
BenmoxinRemifentanil may increase the serotonergic activities of Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Benperidol.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Remifentanil.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Benzocaine.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Remifentanil.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Remifentanil is combined with Benzyl alcohol.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Remifentanil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Remifentanil is combined with Betaxolol.Approved
BevantololRemifentanil may increase the bradycardic activities of Bevantolol.Approved
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Remifentanil.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Remifentanil is combined with Bisoprolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Remifentanil.Investigational
BopindololRemifentanil may increase the bradycardic activities of Bopindolol.Approved
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Remifentanil.Experimental
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Remifentanil.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Remifentanil is combined with Bretylium.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Remifentanil is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Bromazepam.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Remifentanil is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Remifentanil.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololRemifentanil may increase the bradycardic activities of Bucindolol.Investigational
BufuralolRemifentanil may increase the bradycardic activities of Bufuralol.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Bupivacaine.Approved, Investigational
BupranololRemifentanil may increase the bradycardic activities of Bupranolol.Approved
BuprenorphineRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Remifentanil.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Remifentanil.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Remifentanil is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Remifentanil is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Remifentanil is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Remifentanil.Approved, Illicit, Vet Approved
ButylscopolamineThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Remifentanil.Approved, Vet Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Candesartan cilexetil.Approved
CanertinibThe risk or severity of adverse effects can be increased when Remifentanil is combined with Canertinib.Investigational
Canrenoic acidThe risk or severity of adverse effects can be increased when Remifentanil is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Canrenone.Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Remifentanil.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Remifentanil.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Carisoprodol.Approved
CaroxazoneRemifentanil may increase the serotonergic activities of Caroxazone.Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Remifentanil is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Carvedilol.Approved, Investigational
CeliprololRemifentanil may increase the bradycardic activities of Celiprolol.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Remifentanil.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chloroprocaine.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Remifentanil.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Remifentanil.Illicit, Withdrawn
ChlorproethazineChlorproethazine may increase the hypotensive activities of Remifentanil.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Remifentanil.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chlorzoxazone.Approved
CicletanineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cicletanine.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Remifentanil.Approved, Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cinchocaine.Approved, Vet Approved
CitalopramRemifentanil may increase the serotonergic activities of Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Clevidipine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Remifentanil is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Remifentanil.Approved, Investigational
ClofenamideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Clofenamide.Experimental
clomethiazoleThe risk or severity of adverse effects can be increased when Remifentanil is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Clonidine.Approved
ClopamideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Clopamide.Experimental
ClopenthixolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Clopenthixol.Experimental
CloranololRemifentanil may increase the bradycardic activities of Cloranolol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Remifentanil.Approved, Illicit
ClorexoloneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Clorexolone.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Remifentanil.Approved
CocaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Remifentanil.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Remifentanil is combined with Conivaptan.Approved, Investigational
CyclizineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cyclobenzaprine.Approved
CyclopenthiazideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cyclopenthiazide.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Remifentanil.Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dantrolene.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dapiprazole.Approved
DapoxetineRemifentanil may increase the serotonergic activities of Dapoxetine.Investigational
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Remifentanil.Approved, Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Desmopressin.Approved
DesvenlafaxineRemifentanil may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Remifentanil.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Remifentanil.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Remifentanil.Approved, Illicit, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Diclofenamide.Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Remifentanil.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Remifentanil is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may increase the analgesic activities of Remifentanil.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Remifentanil is combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dinutuximab.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dipyridamole.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Doramectin.Vet Approved
DoxazosinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Doxazosin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Remifentanil is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Drotebanol.Experimental, Illicit
DuloxetineRemifentanil may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Remifentanil is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Efonidipine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Eltanolone.Investigational
EluxadolineRemifentanil may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Emepronium is combined with Remifentanil.Experimental
EmpagliflozinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Remifentanil.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Remifentanil is combined with Entacapone.Approved, Investigational
EpanololRemifentanil may increase the bradycardic activities of Epanolol.Experimental
EplerenoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Remifentanil.Approved
EprosartanThe risk or severity of adverse effects can be increased when Remifentanil is combined with Eprosartan.Approved
EscitalopramRemifentanil may increase the serotonergic activities of Escitalopram.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Remifentanil is combined with Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Remifentanil.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Remifentanil is combined with Etacrynic acid.Approved
EtanautineThe risk or severity of adverse effects can be increased when Etanautine is combined with Remifentanil.Experimental
EthanolRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Remifentanil.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Etomidate.Approved
EtoperidoneRemifentanil may increase the serotonergic activities of Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Etybenzatropine is combined with Remifentanil.Experimental
EzogabineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Felbamate.Approved
FelodipineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Remifentanil.Approved
FenquizoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fenquizone.Experimental
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Remifentanil.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Remifentanil.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fexofenadine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Remifentanil.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Flunitrazepam.Approved, Illicit
FluoxetineRemifentanil may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Remifentanil.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Remifentanil.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Remifentanil.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fluvoxamine.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fosinopril.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fospropofol.Approved, Illicit, Investigational
FurazolidoneRemifentanil may increase the serotonergic activities of Furazolidone.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Gabapentin Enacarbil.Approved
GallamineThe risk or severity of adverse effects can be increased when Gallamine is combined with Remifentanil.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Remifentanil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Remifentanil is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GepefrineGepefrine may increase the analgesic activities of Remifentanil.Experimental
GepironeThe risk or severity of adverse effects can be increased when Remifentanil is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Glutethimide.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Remifentanil.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Remifentanil.Approved
HalothaneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Heroin.Approved, Illicit, Investigational
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Remifentanil.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Remifentanil is combined with Hexobarbital.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Remifentanil.Approved
HydracarbazineRemifentanil may increase the serotonergic activities of Hydracarbazine.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Remifentanil.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may increase the analgesic activities of Remifentanil.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Remifentanil.Approved
IbopamineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ibopamine.Experimental
IloperidoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Remifentanil.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Remifentanil.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Imipramine.Approved
IndalpineRemifentanil may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Indapamide.Approved
IndenololRemifentanil may increase the bradycardic activities of Indenolol.Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Remifentanil is combined with Indiplon.Investigational
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Remifentanil.Withdrawn
Iofetamine I-123Iofetamine I-123 may increase the analgesic activities of Remifentanil.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Remifentanil.Approved
IproclozideRemifentanil may increase the serotonergic activities of Iproclozide.Withdrawn
IproniazidRemifentanil may increase the serotonergic activities of Iproniazid.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Remifentanil is combined with Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Remifentanil.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Remifentanil.Approved, Vet Approved
IsosorbideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Isosorbide.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Isradipine.Approved
KetamineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ketobemidone.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Remifentanil.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Lamotrigine.Approved, Investigational
LandiololRemifentanil may increase the bradycardic activities of Landiolol.Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Remifentanil.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Levetiracetam.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Remifentanil is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Levocetirizine.Approved
LevodopaRemifentanil may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranRemifentanil may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Remifentanil.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Remifentanil.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Lidocaine.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Remifentanil.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Lisinopril.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Remifentanil is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Lofentanil.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Remifentanil.Approved, Investigational
LoprazolamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Remifentanil.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Lormetazepam.Approved
LosartanThe risk or severity of adverse effects can be increased when Remifentanil is combined with Losartan.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Remifentanil.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Maprotiline.Approved
MazaticolThe risk or severity of adverse effects can be increased when Mazaticol is combined with Remifentanil.Experimental
MebanazineRemifentanil may increase the serotonergic activities of Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Remifentanil is combined with Mebicar.Experimental
MebutizideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Mebutizide.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Remifentanil.Approved
MeclizineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Medetomidine.Vet Approved
MefrusideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Mefruside.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Remifentanil is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Melperone.Approved, Investigational
MephedroneMephedrone may increase the analgesic activities of Remifentanil.Investigational
MephentermineMephentermine may increase the analgesic activities of Remifentanil.Approved
MepindololRemifentanil may increase the bradycardic activities of Mepindolol.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Remifentanil.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Meptazinol.Experimental
MersalylThe risk or severity of adverse effects can be increased when Remifentanil is combined with Mersalyl.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Remifentanil.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Remifentanil.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Remifentanil.Approved, Investigational
MethapyrileneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Remifentanil.Approved
MethotrimeprazineRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may increase the analgesic activities of Remifentanil.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methylecgonine.Experimental
Methylene blueMethylene blue may increase the hypotensive activities of Remifentanil.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methylphenobarbital.Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Remifentanil.Approved
MeticraneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Meticrane.Experimental
MetipranololThe risk or severity of adverse effects can be increased when Remifentanil is combined with Metipranolol.Approved
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Remifentanil.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Remifentanil is combined with Metoprolol.Approved, Investigational
MetyrosineRemifentanil may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Remifentanil.Approved, Illicit
MidomafetamineMidomafetamine may increase the analgesic activities of Remifentanil.Experimental, Illicit, Investigational
MilnacipranRemifentanil may increase the serotonergic activities of Milnacipran.Approved
MinaprineRemifentanil may increase the serotonergic activities of Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Minoxidil.Approved
MirtazapineRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAMMDA may increase the analgesic activities of Remifentanil.Experimental, Illicit
MoclobemideRemifentanil may increase the serotonergic activities of Moclobemide.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Molindone.Approved
MoricizineMoricizine may increase the hypotensive activities of Remifentanil.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Remifentanil.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Remifentanil.Approved, Investigational
MuzolimineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Muzolimine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Remifentanil is combined with Nadolol.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Remifentanil.Approved
NaltrexoneThe therapeutic efficacy of Remifentanil can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NebivololThe risk or severity of adverse effects can be increased when Remifentanil is combined with Nebivolol.Approved, Investigational
NefazodoneRemifentanil may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NesiritideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Nesiritide.Approved, Investigational
NialamideRemifentanil may increase the serotonergic activities of Nialamide.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Remifentanil.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Nifedipine.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Remifentanil.Approved, Investigational
NimodipineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Nitrazepam.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Remifentanil.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Remifentanil.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Nitroprusside.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Nitrous oxide.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Nortriptyline.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Remifentanil.Approved
OctamoxinRemifentanil may increase the serotonergic activities of Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Remifentanil.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Remifentanil is combined with Olmesartan.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Remifentanil is combined with Opium.Approved, Illicit
OrphenadrineRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Remifentanil is combined with Osanetant.Investigational
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Remifentanil.Experimental, Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Remifentanil.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Oxethazaine.Approved, Investigational
OxitropiumThe risk or severity of adverse effects can be increased when Oxitropium is combined with Remifentanil.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Remifentanil is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Oxybuprocaine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Remifentanil.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Remifentanil.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Remifentanil.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Remifentanil.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Paliperidone.Approved
PamabromThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pamabrom.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Remifentanil.Approved
PapaverineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Papaverine.Approved
ParaldehydeRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylineRemifentanil may increase the serotonergic activities of Pargyline.Approved
ParoxetineRemifentanil may increase the serotonergic activities of Paroxetine.Approved, Investigational
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Remifentanil.Approved
PenbutololThe risk or severity of adverse effects can be increased when Remifentanil is combined with Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Remifentanil.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Remifentanil.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Remifentanil.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved
PerazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Perazine.Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Remifentanil is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Remifentanil.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Remifentanil.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Remifentanil.Approved
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Remifentanil.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Remifentanil is combined with Phenibut.Experimental
PheniprazineRemifentanil may increase the serotonergic activities of Pheniprazine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Remifentanil is combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Phenoperidine.Experimental
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Remifentanil.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Phenoxyethanol.Approved
PhenoxypropazineRemifentanil may increase the serotonergic activities of Phenoxypropazine.Withdrawn
PhenterminePhentermine may increase the analgesic activities of Remifentanil.Approved, Illicit
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Remifentanil.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pimozide.Approved
PindololThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pipamperone.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Remifentanil.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pipotiazine.Approved, Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Remifentanil.Approved
PiretanideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Piretanide.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Piritramide.Investigational
PirlindoleRemifentanil may increase the serotonergic activities of Pirlindole.Approved
PivhydrazineRemifentanil may increase the serotonergic activities of Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pizotifen.Approved
Platelet Activating FactorRemifentanil may increase the bradycardic activities of Platelet Activating Factor.Experimental
PolythiazideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pomalidomide.Approved
PotassiumThe risk or severity of adverse effects can be increased when Remifentanil is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Potassium Citrate.Approved, Vet Approved
PractololRemifentanil may increase the bradycardic activities of Practolol.Approved
PramipexoleRemifentanil may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Prazepam.Approved, Illicit
PrazosinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Prazosin.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Remifentanil.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Procarbazine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Remifentanil.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Remifentanil.Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Remifentanil.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Remifentanil is combined with Propanidid.Experimental
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Remifentanil.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Proparacaine.Approved, Vet Approved
PropericiazinePropericiazine may increase the hypotensive activities of Remifentanil.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Remifentanil.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Remifentanil.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Remifentanil.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Propoxycaine.Approved
PropranololThe risk or severity of adverse effects can be increased when Remifentanil is combined with Propranolol.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Remifentanil is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Remifentanil is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Remifentanil.Approved
QuazepamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Quinapril.Approved, Investigational
QuinethazoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Quinethazone.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Remifentanil.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ramipril.Approved
RamosetronRemifentanil may increase the constipating activities of Ramosetron.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Remifentanil.Approved, Investigational
RiociguatThe risk or severity of adverse effects can be increased when Remifentanil is combined with Riociguat.Approved
RisperidoneRemifentanil may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Remifentanil.Investigational
RolofyllineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Rolofylline.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Romifidine.Vet Approved
RopiniroleRemifentanil may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ropivacaine.Approved
RotigotineRemifentanil may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Remifentanil.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Sacubitril.Approved
SafrazineRemifentanil may increase the serotonergic activities of Safrazine.Withdrawn
ScopolamineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Remifentanil.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Remifentanil is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineRemifentanil may increase the serotonergic activities of Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Sevoflurane.Approved, Vet Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Remifentanil is combined with Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Remifentanil.Approved
SotalolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Sotalol.Approved
SpiradolineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Spiradoline.Investigational
SpironolactoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Spironolactone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Remifentanil is combined with Streptokinase.Approved, Investigational
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Remifentanil.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Remifentanil.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Sultopride.Experimental
SuvorexantRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TalinololRemifentanil may increase the bradycardic activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tasimelteon.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Remifentanil is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Remifentanil.Approved
TerazosinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Terazosin.Approved
TertatololRemifentanil may increase the bradycardic activities of Tertatolol.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tetrodotoxin.Investigational
ThalidomideRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Theobromine.Approved, Investigational
ThiamylalThe risk or severity of adverse effects can be increased when Remifentanil is combined with Thiamylal.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Remifentanil.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Remifentanil.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Remifentanil is combined with Thiopental.Approved, Vet Approved
ThioproperazineThioproperazine may increase the hypotensive activities of Remifentanil.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Remifentanil.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tiapride.Approved, Investigational
TicrynafenThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tilidine.Experimental
TimololThe risk or severity of adverse effects can be increased when Remifentanil is combined with Timolol.Approved
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Remifentanil.Approved
TizanidineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tizanidine.Approved
TolazolineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tolcapone.Approved, Withdrawn
ToloxatoneRemifentanil may increase the serotonergic activities of Toloxatone.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Remifentanil.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Remifentanil.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Trazodone.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Remifentanil.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Remifentanil.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Triflupromazine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Remifentanil.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Remifentanil.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Triprolidine.Approved
TropatepineThe risk or severity of adverse effects can be increased when Tropatepine is combined with Remifentanil.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Remifentanil.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Remifentanil.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Remifentanil.Approved
UlaritideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ularitide.Investigational
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Remifentanil.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Remifentanil is combined with Valproic Acid.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Remifentanil is combined with Valsartan.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Remifentanil.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Remifentanil.Approved
VenlafaxineRemifentanil may increase the serotonergic activities of Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Veralipride.Experimental
VerapamilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Remifentanil is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Remifentanil is combined with Xenon.Experimental
XipamideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Xipamide.Experimental
XylazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Remifentanil is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ziconotide.Approved
ZimelidineRemifentanil may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Remifentanil.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Zolazepam.Vet Approved
ZolpidemRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Jacob Mathew, J. Killgore, "New methods for the synthesis of alfentanil, sufentanil, and remifentanil." U.S. Patent US20060149071, issued July 06, 2006.

US20060149071
General References
Not Available
External Links
Human Metabolome Database
HMDB15036
KEGG Compound
C08021
PubChem Compound
60815
PubChem Substance
46504538
ChemSpider
54803
BindingDB
50012491
ChEBI
8802
ChEMBL
CHEMBL1005
Therapeutic Targets Database
DAP000264
PharmGKB
PA451232
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Remifentanil
ATC Codes
N01AH06 — Remifentanil
AHFS Codes
  • 28:08.08 — Opiate Agonists
FDA label
Download (380 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingBasic ScienceSleep Apnea Syndrome1
1CompletedNot AvailablePain1
1CompletedDiagnosticDepth of Anaesthesia1
1CompletedTreatmentPain / Stress1
1RecruitingHealth Services ResearchRespiratory Depression1
1Unknown StatusSupportive CareSleep Apnea, Obstructive1
1, 2Active Not RecruitingPreventionAnaesthesia therapy / Cesarean Section1
1, 2CompletedSupportive CareInfant, Preterm1
1, 2CompletedTreatmentDrug Overdose1
1, 2CompletedTreatmentHematologic Diseases / Neoplasms1
1, 2CompletedTreatmentPain, Acute / Respiration stimulated / Sedation therapy1
1, 2TerminatedSupportive CareMechanical Ventilator Care / Preterm Infants1
2CompletedPreventionPregnancy / Severe Pre-eclampsia1
2CompletedSupportive CareIdiopathic Scoliosis1
2CompletedTreatmentAnaesthesia therapy / Hysterectomy / Ketamine / Morphine1
2CompletedTreatmentProgressive Infantile Idiopathic Scoliosis1
2CompletedTreatmentAdjunct to general anesthesia therapy1
2RecruitingTreatmentHyperalgesia1
2RecruitingTreatmentPain, Acute1
2TerminatedBasic ScienceHealthy Volunteers1
2, 3Not Yet RecruitingTreatmentAnalgesia, Obstetrical / Obstetrical Anesthesia / Postpartum Depression1
2, 3Unknown StatusTreatmentObesity, Morbid1
3CompletedNot AvailableCognitive Ability, General1
3CompletedSupportive CareArterial Hypotension / Bradycardia1
3CompletedSupportive CareTumor of Ear, Nose and Throat1
3CompletedTreatmentAnaesthesia therapy1
3CompletedTreatmentAnaesthesia therapy / Craniotomy / Neurosurgery1
3CompletedTreatmentBreech Presentation / Pregnancy1
3CompletedTreatmentComplications, Pregnancy / Complications; Cesarean Section / Fetus or Neonate Affected by External Version Before Labor / Inhalation of Nitrous Oxide / Non-cephalic Presentation1
3CompletedTreatmentIntubation, Endotracheal1
3CompletedTreatmentSpinal Puncture1
3CompletedTreatmentVentilations, Mechanical1
3Not Yet RecruitingTreatmentAnaesthesia therapy / Opioid-Related Disorders1
3RecruitingTreatmentAnaesthesia therapy / Child's Development / Neurotoxicity1
3RecruitingTreatmentStrokes1
3TerminatedTreatmentAnalgesia1
3Unknown StatusBasic SciencePostherpetic Neuralgia1
4Active Not RecruitingNot AvailableCardiac Diseases1
4Active Not RecruitingPreventionHeart Diseases / Hyperglycemias1
4Active Not RecruitingTreatmentAnaesthesia therapy1
4CompletedNot AvailableAnaesthesia therapy1
4CompletedNot AvailableIntubation, Endotracheal1
4CompletedNot AvailablePatients Requiring Ambulatory Surgery Under General Anesthesia1
4CompletedBasic ScienceAnaesthesia therapy1
4CompletedBasic ScienceHealthy Volunteers1
4CompletedBasic SciencePharyngeal Dysfunction / Pharyngeal Swallowing1
4CompletedBasic ScienceSecondary Hyperalgesia1
4CompletedDiagnosticAlteration of Cognitive Function / Gastrointestinal Dysfunction1
4CompletedDiagnosticAnaesthesia therapy / Electroencephalography/ Drug Effect1
4CompletedDiagnosticAutonomic Nervous System Activity1
4CompletedPreventionAcute Agitation1
4CompletedPreventionAnaesthesia therapy / Palonosetron / Ponv1
4CompletedPreventionAortic Valve Stenosis / Ischaemic Heart Diseases1
4CompletedPreventionCervical Disc Herniation / Cervical Spinal Stenosis / Cervical Spine Damage1
4CompletedPreventionChronic Rhinosinusitis1
4CompletedPreventionCoronary Artery Disease1
4CompletedPreventionCoughing1
4CompletedPreventionDrug Usage1
4CompletedPreventionElective Thyroidectomy1
4CompletedPreventionFentanyl / Pain, Chronic / Remifentanil / Sternotomy1
4CompletedPreventionHyperalgesia2
4CompletedPreventionIntubation, Endotracheal1
4CompletedPreventionMyocardial Ischemic Reperfusion Injury1
4CompletedPreventionOpen Craniotomy1
4CompletedPreventionPostoperative Confusion1
4CompletedPreventionPostoperative pain2
4CompletedPreventionSupratentorial Neoplasms1
4CompletedPreventionThyroidectomy1
4CompletedPreventionUpper Respiratory Infections1
4CompletedScreeningAnaesthesia therapy / Neuromuscular Blockade1
4CompletedScreeningPatients Undergoing Major Abdominal Surgery / Postoperative Confusion1
4CompletedSupportive CareColonoscopy1
4CompletedSupportive CareHypothermia1
4CompletedSupportive CareIntubation; Difficult1
4CompletedSupportive CareRespiratory Distress Syndrome (RDS)1
4CompletedSupportive CareTranscervical Resection of Endometrium / Transcervical Resection of Fibroids / Transcervical Resection of Polyp1
4CompletedSupportive CareUnderdosing of Unspecified General Anesthetics1
4CompletedTreatmentAdverse Effects / Labour Pain / Satisfaction1
4CompletedTreatmentAnaesthesia therapy2
4CompletedTreatmentAnesthetics / Anesthetics, Intravenous / Cardiopulmonary Bypass / Pharmacology1
4CompletedTreatmentChronic Calculous Cholecystitis1
4CompletedTreatmentCoughing / High Blood Pressure (Hypertension)1
4CompletedTreatmentDeep Sedation / Delayed Emergence From Anesthesia1
4CompletedTreatmentDiagnostic Colonoscopy Screening1
4CompletedTreatmentDrug Usage1
4CompletedTreatmentEfficacy and Safety of Mivacurium Chloride for Pediatric Patients1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Myocardial Ischemia / Tachycardia1
4CompletedTreatmentInduction of Anaesthesia1
4CompletedTreatmentLabour Pain1
4CompletedTreatmentLabour / Pain1
4CompletedTreatmentLung Function1
4CompletedTreatmentMuscle Relaxation1
4CompletedTreatmentOpioid Induced Pharyngeal and Esophageal Dysfunction1
4CompletedTreatmentOpioid Induced Swallowing Disorders1
4CompletedTreatmentOsteoarthritis (OA) / Pain, Chronic1
4CompletedTreatmentPain4
4CompletedTreatmentPain Relief in Labour1
4CompletedTreatmentFunctional disorders of the biliary tract / Pancreatic Diseases1
4CompletedTreatmentPancreatic Stone Disease1
4CompletedTreatmentPediatric Rigid Bronchoscopy1
4CompletedTreatmentRenal Stones1
4CompletedTreatmentRespiration, Artificial / Respiratory Insufficiency / Sedation, Conscious1
4CompletedTreatmentSedation therapy1
4CompletedTreatmentSupraglottic Airways for General Anesthesia1
4CompletedTreatmentSurgical Procedures, Operative1
4CompletedTreatmentTachycardia1
4CompletedTreatmentTooth Extractions1
4CompletedTreatmentTracheal Extubation1
4CompletedTreatmentUrinary Tract Problem1
4CompletedTreatmentVentricular Tachycardia (VT)1
4CompletedTreatmentAdjunct to general anesthesia therapy1
4Enrolling by InvitationPreventionAnesthesia, Intratracheal / Hernia / Intravenous Anesthesia / Pain, Acute / Pain, Chronic1
4Enrolling by InvitationSupportive CareHemodynamics Instability1
4Not Yet RecruitingBasic SciencePharyngeal Dysfunction / Pharyngeal Swallowing1
4Not Yet RecruitingPreventionCritical Illness1
4Not Yet RecruitingPreventionDrug Usage1
4Not Yet RecruitingScreeningCerebral Oxygen Saturation / Hypotension Drug-Induced1
4Not Yet RecruitingSupportive CareIntubating Conditions1
4Not Yet RecruitingTreatmentAnaesthesia therapy / Electroconvulsive Therapy1
4RecruitingNot AvailableGeneral Surgery1
4RecruitingDiagnosticBispectral Index / Induction of anesthesia therapy / Target Controlled Infusion (TCI)1
4RecruitingPreventionEndovascular Repair of Aortic Aneurysm / Endovascular Treatment of Arteriosclerosis Obliterans of Lower Extremities1
4RecruitingPreventionIntra-abdominal and Intrapelvic Surgery / Intra-abdominal Surgery1
4RecruitingPreventionSleep Apnea Syndromes / Sleep Apnea, Obstructive1
4RecruitingSupportive CareAnaesthesia therapy1
4RecruitingSupportive CareAnesthesia, Conduction / Drug Interactions1
4RecruitingSupportive CareLocal Anesthesia1
4RecruitingTreatmentLabour Pain1
4RecruitingTreatmentPostoperative pain1
4RecruitingTreatmentRespiratory Distress Syndrome, Newborn1
4TerminatedDiagnosticVentricular Dysfunction / Young Healthy Adults1
4TerminatedPreventionCarotid Artery Stenosis1
4TerminatedSupportive CarePain1
4TerminatedTreatmentAnaesthesia therapy1
4TerminatedTreatmentAnalgesia / Sedation therapy1
4TerminatedTreatmentAnesthesia Recovery Period / Postoperative pain1
4TerminatedTreatmentMinor burns / Pain1
4Unknown StatusNot AvailableComplications, Pregnancy / Hypertension, Pregnancy-Induced / Prophylaxis of preeclampsia1
4Unknown StatusNot AvailableDeviation Septum Nasal1
4Unknown StatusNot AvailablePolyps, Nasal1
4Unknown StatusBasic ScienceHyperalgesia4
4Unknown StatusPreventionAcute Agitation1
4Unknown StatusPreventionDelirium1
4Unknown StatusSupportive CareLung Cancers1
4Unknown StatusTreatmentAdrenal Suppression / Hemodynamics Instability1
4Unknown StatusTreatmentAnaesthesia therapy / Hemodynamics / Oxidative Stress1
4Unknown StatusTreatmentGoiter, Nodular1
4Unknown StatusTreatmentHaemodynamic Rebound1
4Unknown StatusTreatmentHemodynamics / Hysteroscopy / Sedation therapy1
Not AvailableCompletedNot AvailableAnaesthesia therapy2
Not AvailableCompletedNot AvailableAnaesthesia therapy / Effects of Dexmedetomidine / Elderly Patients / Emergence From Anesthesia / Recovery From Anesthesia1
Not AvailableCompletedNot AvailableAnalgesia1
Not AvailableCompletedNot AvailableCardiac Dysrhythmia / Coronary Artery Bypass Graft / Dexmedetomidine / Hypokalaemia / Remifentanil1
Not AvailableCompletedNot AvailableComplication of Labor and/or Delivery1
Not AvailableCompletedNot AvailableEpilepsies1
Not AvailableCompletedNot AvailableHead and Neck Disorder / Pain1
Not AvailableCompletedNot AvailableHypotension, Controlled1
Not AvailableCompletedNot AvailableTraumatic Brain Injury (TBI)1
Not AvailableCompletedBasic ScienceCritical Care / Deep Sedation / Sedation, Conscious1
Not AvailableCompletedBasic ScienceDrug Overdose1
Not AvailableCompletedBasic ScienceLumbar Surgery1
Not AvailableCompletedDiagnosticAnaesthesia therapy1
Not AvailableCompletedDiagnosticCancer, Ovarian / Cervical Cancers / Gallbladder Inflammation / Ovarian Cysts / Uterine Leiomyomas1
Not AvailableCompletedHealth Services ResearchPain1
Not AvailableCompletedOtherObese1
Not AvailableCompletedPreventionAVM / ICH / Neoplasms, Brain1
Not AvailableCompletedPreventionAnaesthesia therapy / Coughing2
Not AvailableCompletedPreventionAnaesthesia therapy / Coughing / Extubation1
Not AvailableCompletedPreventionAnaesthesia therapy / Pain1
Not AvailableCompletedPreventionAdjunct to general anesthesia therapy / Cesarean Delivery / Pregnancy1
Not AvailableCompletedPreventionGeneral Surgery With Endotracheal Intubation1
Not AvailableCompletedPreventionGeneral Surgery / Prostate Cancer1
Not AvailableCompletedPreventionHealthy Volunteers2
Not AvailableCompletedPreventionHemodynamic Responses During Tracheal Intubation1
Not AvailableCompletedPreventionIntubation, Intratracheal1
Not AvailableCompletedPreventionPain2
Not AvailableCompletedPreventionPostoperative pain1
Not AvailableCompletedPreventionRespiratory Complications2
Not AvailableCompletedPreventionStroke, Ischemic1
Not AvailableCompletedPreventionThyroidectomy1
Not AvailableCompletedPreventionVitrectomy Operation Under General Anesthesia1
Not AvailableCompletedPreventionVocal Cord; Injury, Superficial1
Not AvailableCompletedScreeningGeneral Surgery / Pain1
Not AvailableCompletedSupportive CareC.Delivery; Surgery (Previous), Gynecological / Delayed Emergence From Anesthesia / Inappropriate Device Stimulation of Tissue1
Not AvailableCompletedSupportive CareCataracts / Corneal Inflammation / Pterygium / Retina Detachment / Vitreous Hemorrhage1
Not AvailableCompletedSupportive CareHyperalgesia / Ibuprofen / Postoperative pain / Remifentanil1
Not AvailableCompletedSupportive CarePain1
Not AvailableCompletedSupportive CarePatients Undergoing Laparoscopic Gastrectomy1
Not AvailableCompletedSupportive CareStrabismus1
Not AvailableCompletedTreatmentAdult Intracranial Tumor / Adult Solid Tumor1
Not AvailableCompletedTreatmentAdverse Effect of Other General Anesthetics1
Not AvailableCompletedTreatmentAnaesthesia therapy1
Not AvailableCompletedTreatmentAnaesthesia therapy / Neuromuscular Blockade1
Not AvailableCompletedTreatmentAnaesthesia therapy / Pain1
Not AvailableCompletedTreatmentAnxiety Preoperative / Midazolam Premedication / Premedication1
Not AvailableCompletedTreatmentDrug Usage1
Not AvailableCompletedTreatmentFractures, Compression1
Not AvailableCompletedTreatmentIschaemic Heart Diseases1
Not AvailableCompletedTreatmentNeoplasms, Brain1
Not AvailableCompletedTreatmentOsteoarthritis (OA)2
Not AvailableCompletedTreatmentPain2
Not AvailableCompletedTreatmentPain, Chronic1
Not AvailableCompletedTreatmentPostoperative Cognitive Functions1
Not AvailableCompletedTreatmentPostoperative Complications1
Not AvailableCompletedTreatmentPostoperative pain1
Not AvailableCompletedTreatmentPregnancy Termination1
Not AvailableCompletedTreatmentShort Duration Analgesia / Skull Pin Insertion1
Not AvailableCompletedTreatmentSurgical Blood Loss1
Not AvailableEnrolling by InvitationScreeningAnaesthesia therapy / General Surgery / Ophthalmic1
Not AvailableNot Yet RecruitingPreventionPeripheral Obliterative Arteriopathy1
Not AvailableNot Yet RecruitingSupportive CareCardiovascular Disease (CVD)1
Not AvailableNot Yet RecruitingTreatmentBrain / Sedation therapy1
Not AvailableRecruitingNot AvailableAnaesthesia therapy1
Not AvailableRecruitingNot AvailableGeneral Anesthetics Toxicity / Lymphocyte Destruction / Metastatic Colorectal Cancers / Molecular Mechanism of Pharmacological Action / Survival Rate1
Not AvailableRecruitingNot AvailableLabor; Prolonged, First Stage / Labor; Prolonged, Second Stage / Labour Pain1
Not AvailableRecruitingNot AvailableShort Stature1
Not AvailableRecruitingBasic SciencePain1
Not AvailableRecruitingDiagnosticAnaesthesia therapy / Pain1
Not AvailableRecruitingPreventionDelirium1
Not AvailableRecruitingPreventionNeoplasms, Thyroid1
Not AvailableRecruitingPreventionProphylaxis against postoperative nausea and vomiting1
Not AvailableRecruitingSupportive CareInguinal Hernias / Postoperative pain1
Not AvailableRecruitingSupportive CarePostoperative pain / Undescended Testis1
Not AvailableRecruitingTreatmentAcute Hypercapnic Respiratory Failure1
Not AvailableRecruitingTreatmentAnaesthesia therapy / Children / Pain1
Not AvailableRecruitingTreatmentColonoscopy1
Not AvailableTerminatedNot AvailableAnaesthesia therapy1
Not AvailableTerminatedDiagnosticParkinson's Disease (PD)1
Not AvailableTerminatedPreventionGeneral Surgery1
Not AvailableTerminatedTreatmentAnaesthesia therapy / Surgery, Cardiac1
Not AvailableTerminatedTreatmentChronic Rhinosinusitis1
Not AvailableTerminatedTreatmentPain1
Not AvailableTerminatedTreatmentShoulder Dislocation1
Not AvailableTerminatedTreatmentAdjunct to general anesthesia therapy1
Not AvailableUnknown StatusNot AvailableLung Cancers / Neoplasms, Lung1
Not AvailableUnknown StatusNot AvailablePediatrics1
Not AvailableUnknown StatusBasic ScienceEffect of Remifentanil / Movement Disorders1
Not AvailableUnknown StatusBasic ScienceLaryngoscopy1
Not AvailableUnknown StatusPreventionIntubation, Intratracheal1
Not AvailableUnknown StatusPreventionPain1
Not AvailableUnknown StatusSupportive CareAdjunct to general anesthesia therapy1
Not AvailableUnknown StatusTreatmentHaemodynamic Fluctuations During Off-pump CABG1
Not AvailableWithdrawnPreventionNeoplasms, Brain1

Pharmacoeconomics

Manufacturers
  • Bioniche teoranta
Packagers
Dosage forms
FormRouteStrength
Powder, for solutionIntravenous1 mg
Powder, for solutionIntravenous2 mg
Injection, powder, lyophilized, for solutionIntravenous1 mg/mL
Powder, for solutionIntravenous5 mg
Prices
Unit descriptionCostUnit
Ultiva 5 mg vial118.15USD vial
Ultiva 2 mg vial57.2USD vial
Ultiva 1 mg vial30.19USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5019583No1993-07-122010-07-12Us
US5866591Yes1998-03-102018-03-10Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP1.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.591 mg/mLALOGPS
logP1.75ALOGPS
logP1.52ChemAxon
logS-2.8ALOGPS
pKa (Strongest Basic)7.51ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area76.15 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity100.56 m3·mol-1ChemAxon
Polarizability40.82 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.6136
Blood Brain Barrier+0.9381
Caco-2 permeable-0.5271
P-glycoprotein substrateSubstrate0.7345
P-glycoprotein inhibitor IInhibitor0.8682
P-glycoprotein inhibitor IINon-inhibitor0.6428
Renal organic cation transporterNon-inhibitor0.7077
CYP450 2C9 substrateNon-substrate0.8041
CYP450 2D6 substrateNon-substrate0.8786
CYP450 3A4 substrateSubstrate0.6963
CYP450 1A2 substrateNon-inhibitor0.9355
CYP450 2C9 inhibitorNon-inhibitor0.8788
CYP450 2D6 inhibitorNon-inhibitor0.8838
CYP450 2C19 inhibitorNon-inhibitor0.8201
CYP450 3A4 inhibitorNon-inhibitor0.7827
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7945
Ames testNon AMES toxic0.7388
CarcinogenicityNon-carcinogens0.8554
BiodegradationNot ready biodegradable0.9428
Rat acute toxicity2.6994 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9589
hERG inhibition (predictor II)Inhibitor0.6126
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004i-0009000000-b9035e2706d5ac9b57a7
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-02di-0397000000-c610a2d0adc44d55166b
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0930000000-436dbd271b442dcde5bf
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03e9-4900000000-79234a6e65fb22f3b487
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-01q9-9700000000-5ce11ade40e1a80e4958

Taxonomy

Description
This compound belongs to the class of organic compounds known as alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Alpha amino acids and derivatives
Alternative Parents
Piperidinecarboxylic acids / Anilides / Dicarboxylic acids and derivatives / Tertiary carboxylic acid amides / Methyl esters / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
show 1 more
Substituents
Alpha-amino acid or derivatives / Piperidinecarboxylic acid / Anilide / Monocyclic benzene moiety / Dicarboxylic acid or derivatives / Piperidine / Benzenoid / Tertiary carboxylic acid amide / Methyl ester / Carboxamide group
show 15 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
monocarboxylic acid amide, alpha-amino acid ester, anilide, piperidinecarboxylate ester (CHEBI:8802)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Voltage-gated calcium channel activity
Specific Function
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
Gene Name
OPRM1
Uniprot ID
P35372
Uniprot Name
Mu-type opioid receptor
Molecular Weight
44778.855 Da
References
  1. Scott LJ, Perry CM: Remifentanil: a review of its use during the induction and maintenance of general anaesthesia. Drugs. 2005;65(13):1793-823. [PubMed:16114980]
  2. Scott LJ, Perry CM: Spotlight on remifentanil for general anaesthesia. CNS Drugs. 2005;19(12):1069-74. [PubMed:16332149]
  3. Warner DS, Hindman BJ, Todd MM, Sawin PD, Kirchner J, Roland CL, Jamerson BD: Intracranial pressure and hemodynamic effects of remifentanil versus alfentanil in patients undergoing supratentorial craniotomy. Anesth Analg. 1996 Aug;83(2):348-53. [PubMed:8694317]
  4. Guy J, Hindman BJ, Baker KZ, Borel CO, Maktabi M, Ostapkovich N, Kirchner J, Todd MM, Fogarty-Mack P, Yancy V, Sokoll MD, McAllister A, Roland C, Young WL, Warner DS: Comparison of remifentanil and fentanyl in patients undergoing craniotomy for supratentorial space-occupying lesions. Anesthesiology. 1997 Mar;86(3):514-24. [PubMed:9066316]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  6. Hoke JF, Cunningham F, James MK, Muir KT, Hoffman WE: Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. J Pharmacol Exp Ther. 1997 Apr;281(1):226-32. [PubMed:9103501]
  7. Patel SS, Spencer CM: Remifentanil. Drugs. 1996 Sep;52(3):417-27; discussion 428. [PubMed:8875131]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine n...
Gene Name
OPRD1
Uniprot ID
P41143
Uniprot Name
Delta-type opioid receptor
Molecular Weight
40368.235 Da
References
  1. Stucke AG, Zuperku EJ, Sanchez A, Tonkovic-Capin M, Tonkovic-Capin V, Mustapic S, Stuth EA: Opioid receptors on bulbospinal respiratory neurons are not activated during neuronal depression by clinically relevant opioid concentrations. J Neurophysiol. 2008 Nov;100(5):2878-88. doi: 10.1152/jn.90620.2008. Epub 2008 Sep 24. [PubMed:18815346]
  2. Rodrigues AR, Castro MS, Francischi JN, Perez AC, Duarte ID: Participation of ATP-sensitive K+ channels in the peripheral antinociceptive effect of fentanyl in rats. Braz J Med Biol Res. 2005 Jan;38(1):91-7. Epub 2005 Jan 18. [PubMed:15665994]
  3. Poonawala T, Levay-Young BK, Hebbel RP, Gupta K: Opioids heal ischemic wounds in the rat. Wound Repair Regen. 2005 Mar-Apr;13(2):165-74. [PubMed:15828941]
  4. Sahin AS, Duman A, Atalik EK, Ogun CO, Sahin TK, Erol A, Ozergin U: The mechanisms of the direct vascular effects of fentanyl on isolated human saphenous veins in vitro. J Cardiothorac Vasc Anesth. 2005 Apr;19(2):197-200. [PubMed:15868528]
  5. Darwish M, Tempero K, Kirby M, Thompson J: Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. Clin Pharmacokinet. 2005;44(12):1279-86. [PubMed:16372825]
  6. Darwish M, Kirby M, Robertson P Jr, Tracewell W, Jiang JG: Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers. Clin Ther. 2006 May;28(5):707-14. [PubMed:16861092]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synt...
Gene Name
OPRK1
Uniprot ID
P41145
Uniprot Name
Kappa-type opioid receptor
Molecular Weight
42644.665 Da
References
  1. Wong GT, Li R, Jiang LL, Irwin MG: Remifentanil post-conditioning attenuates cardiac ischemia-reperfusion injury via kappa or delta opioid receptor activation. Acta Anaesthesiol Scand. 2010 Apr;54(4):510-8. doi: 10.1111/j.1399-6576.2009.02145.x. Epub 2009 Oct 29. [PubMed:19878098]
  2. Pascoe JE, Williams KL, Mukhopadhyay P, Rice KC, Woods JH, Ko MC: Effects of mu, kappa, and delta opioid receptor agonists on the function of hypothalamic-pituitary-adrenal axis in monkeys. Psychoneuroendocrinology. 2008 May;33(4):478-86. doi: 10.1016/j.psyneuen.2008.01.006. Epub 2008 Mar 5. [PubMed:18325678]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18